Hemophilia A Management

Here is a link to New Frontiers in Hemophilia A Management [click], which appears in the December 2020 Clinical Laboratory News, an AACC Publication. The article features the rapid increase of emicizumab [HemLibra®] therapy and the need for bovine substrate chromogenic factor VIII assays to replace the unreliable clot-based assays. The article is a good source of clinical and laboratory information.